Chronic Obstructive Pulmonary Disease | Access and Reimbursement | US | 2017
Current market-leading therapies in the U.S. COPD market will face challenges from emerging drugs, especially generic versions of Spiriva, Symbicort, and Advair. Surveyed physicians often report that familiarity is a key driver of drug selection within a class, but clinical factors are significant both for physicians and MCOs. Cost-control measures are critical for MCOs, and have a moderate impact on prescribing decisions.
Pharmacoeconomic data are anticipated to be of increasing importance, especially with the launch of additional therapies within the LABA/LAMA class and the new LABA/LAMA/ICS FDC class.
Related Market Assessment Reports
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
